DK3182128T3 - ROSE KINASE FOR LUNG CANCER - Google Patents

Info

Publication number

DK3182128T3

DK3182128T3 DK16196573.6T DK16196573T DK3182128T3 DK 3182128 T3 DK3182128 T3 DK 3182128T3 DK 16196573 T DK16196573 T DK 16196573T DK 3182128 T3 DK3182128 T3 DK 3182128T3

Authority

DK

Denmark

Prior art keywords

ros

polypeptide

fusion

protein

cancer

Prior art date

2011-05-23

Links

• Espacenet
• Global Dossier
• Discuss

• 208000020816 lung neoplasm Diseases 0.000 title claims description 112
• 206010058467 Lung neoplasm malignant Diseases 0.000 title claims description 108
• 201000005202 lung cancer Diseases 0.000 title claims description 108
• 108091000080 Phosphotransferase Proteins 0.000 title description 49
• 102000020233 phosphotransferase Human genes 0.000 title description 49
• 241000220317 Rosa Species 0.000 title 1
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 401
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 310
• 229920001184 polypeptide Polymers 0.000 claims description 283
• 230000004927 fusion Effects 0.000 claims description 217
• 206010028980 Neoplasm Diseases 0.000 claims description 209
• 238000000034 method Methods 0.000 claims description 184
• 102000040430 polynucleotide Human genes 0.000 claims description 94
• 108091033319 polynucleotide Proteins 0.000 claims description 94
• 239000002157 polynucleotide Substances 0.000 claims description 94
• 239000012472 biological sample Substances 0.000 claims description 82
• 241000282414 Homo sapiens Species 0.000 claims description 79
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 68
• 238000003556 assay Methods 0.000 claims description 46
• 238000004458 analytical method Methods 0.000 claims description 44
• 239000002773 nucleotide Substances 0.000 claims description 36
• 125000003729 nucleotide group Chemical group 0.000 claims description 36
• 238000001514 detection method Methods 0.000 claims description 28
• 210000004072 lung Anatomy 0.000 claims description 26
• 238000000684 flow cytometry Methods 0.000 claims description 14
• 238000010166 immunofluorescence Methods 0.000 claims description 14
• 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 10
• 239000002853 nucleic acid probe Substances 0.000 claims description 10
• 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 9
• 238000002965 ELISA Methods 0.000 claims description 9
• 102000004190 Enzymes Human genes 0.000 claims description 9
• 108090000790 Enzymes Proteins 0.000 claims description 9
• 238000001574 biopsy Methods 0.000 claims description 9
• 238000002944 PCR assay Methods 0.000 claims description 8
• 238000003757 reverse transcription PCR Methods 0.000 claims description 8
• 238000007901 in situ hybridization Methods 0.000 claims description 6
• 238000002271 resection Methods 0.000 claims description 6
• 230000002055 immunohistochemical effect Effects 0.000 claims description 3
• 210000000416 exudates and transudate Anatomy 0.000 claims 2
• 238000013188 needle biopsy Methods 0.000 claims 2
• 238000007899 nucleic acid hybridization Methods 0.000 claims 1
• 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 605
• 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 603
• 210000004027 cell Anatomy 0.000 description 195
• 230000000694 effects Effects 0.000 description 184
• 108090000623 proteins and genes Proteins 0.000 description 140
• 201000011510 cancer Diseases 0.000 description 107
• 102000004169 proteins and genes Human genes 0.000 description 98
• 239000003153 chemical reaction reagent Substances 0.000 description 88
• 239000000523 sample Substances 0.000 description 88
• 230000014509 gene expression Effects 0.000 description 85
• 235000018102 proteins Nutrition 0.000 description 83
• 230000002401 inhibitory effect Effects 0.000 description 78
• 230000001225 therapeutic effect Effects 0.000 description 70
• 108020001507 fusion proteins Proteins 0.000 description 66
• 102000037865 fusion proteins Human genes 0.000 description 64
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 59
• 239000000203 mixture Substances 0.000 description 58
• 239000003814 drug Substances 0.000 description 49
• 235000001014 amino acid Nutrition 0.000 description 47
• 229940024606 amino acid Drugs 0.000 description 45
• 210000001519 tissue Anatomy 0.000 description 45
• 150000001413 amino acids Chemical class 0.000 description 43
• 230000027455 binding Effects 0.000 description 43
• 150000001875 compounds Chemical class 0.000 description 43
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 42
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 39
• QQWUGDVOUVUTOY-UHFFFAOYSA-N 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)C(C)C QQWUGDVOUVUTOY-UHFFFAOYSA-N 0.000 description 36
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 32
• 239000012634 fragment Substances 0.000 description 32
• 239000003112 inhibitor Substances 0.000 description 32
• 230000005945 translocation Effects 0.000 description 32
• 229960005061 crizotinib Drugs 0.000 description 31
• 125000003275 alpha amino acid group Chemical group 0.000 description 30
• 210000000349 chromosome Anatomy 0.000 description 29
• 238000011282 treatment Methods 0.000 description 28
• 238000003364 immunohistochemistry Methods 0.000 description 27
• 229940079593 drug Drugs 0.000 description 26
• 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 25
• 108020004459 Small interfering RNA Proteins 0.000 description 24
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 22
• 239000002146 L01XE16 - Crizotinib Substances 0.000 description 22
• 238000005516 engineering process Methods 0.000 description 22
• 150000007523 nucleic acids Chemical class 0.000 description 22
• 238000001228 spectrum Methods 0.000 description 21
• 239000000427 antigen Substances 0.000 description 20
• 108091007433 antigens Proteins 0.000 description 20
• 102000036639 antigens Human genes 0.000 description 20
• 238000003752 polymerase chain reaction Methods 0.000 description 20
• 101150042287 ros gene Proteins 0.000 description 20
• 238000001262 western blot Methods 0.000 description 20
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 19
• 230000009368 gene silencing by RNA Effects 0.000 description 19
• 230000026731 phosphorylation Effects 0.000 description 19
• 238000006366 phosphorylation reaction Methods 0.000 description 19
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
• 230000001594 aberrant effect Effects 0.000 description 18
• 201000010099 disease Diseases 0.000 description 18
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
• 150000002500 ions Chemical class 0.000 description 18
• 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 17
• -1 CEP11988 Chemical compound 0.000 description 17
• 238000009472 formulation Methods 0.000 description 17
• 230000005764 inhibitory process Effects 0.000 description 17
• 241001465754 Metazoa Species 0.000 description 16
• 210000004369 blood Anatomy 0.000 description 16
• 239000008280 blood Substances 0.000 description 16
• 102000039446 nucleic acids Human genes 0.000 description 16
• 108020004707 nucleic acids Proteins 0.000 description 16
• 238000010561 standard procedure Methods 0.000 description 16
• 108010001441 Phosphopeptides Proteins 0.000 description 15
• 125000000539 amino acid group Chemical group 0.000 description 15
• 239000002299 complementary DNA Substances 0.000 description 15
• 239000002502 liposome Substances 0.000 description 15
• 108020004414 DNA Proteins 0.000 description 14
• 241000124008 Mammalia Species 0.000 description 14
• 108091006576 SLC34A2 Proteins 0.000 description 14
• 102100038437 Sodium-dependent phosphate transport protein 2B Human genes 0.000 description 14
• 230000005754 cellular signaling Effects 0.000 description 13
• 208000000587 small cell lung carcinoma Diseases 0.000 description 13
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 12
• 108091028043 Nucleic acid sequence Proteins 0.000 description 12
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
• 238000009396 hybridization Methods 0.000 description 12
• 150000003384 small molecules Chemical class 0.000 description 12
• 239000000243 solution Substances 0.000 description 12
• 102000035195 Peptidases Human genes 0.000 description 11
• 108091005804 Peptidases Proteins 0.000 description 11
• 239000000284 extract Substances 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 230000012010 growth Effects 0.000 description 11
• 238000010186 staining Methods 0.000 description 11
• 239000013598 vector Substances 0.000 description 11
• 102100036675 Golgi-associated PDZ and coiled-coil motif-containing protein Human genes 0.000 description 10
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 10
• 101001072499 Homo sapiens Golgi-associated PDZ and coiled-coil motif-containing protein Proteins 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 238000012216 screening Methods 0.000 description 10
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
• 239000004365 Protease Substances 0.000 description 9
• 230000037396 body weight Effects 0.000 description 9
• 230000000875 corresponding effect Effects 0.000 description 9
• 238000003018 immunoassay Methods 0.000 description 9
• 238000004519 manufacturing process Methods 0.000 description 9
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 9
• 238000004885 tandem mass spectrometry Methods 0.000 description 9
• 241000283973 Oryctolagus cuniculus Species 0.000 description 8
• 208000002151 Pleural effusion Diseases 0.000 description 8
• 102000001253 Protein Kinase Human genes 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 230000000692 anti-sense effect Effects 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 230000000670 limiting effect Effects 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• 230000008707 rearrangement Effects 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• 241000894007 species Species 0.000 description 8
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
• 108091026890 Coding region Proteins 0.000 description 7
• 230000003321 amplification Effects 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 230000000903 blocking effect Effects 0.000 description 7
• 210000005266 circulating tumour cell Anatomy 0.000 description 7
• 101150016193 fig gene Proteins 0.000 description 7
• 229940043355 kinase inhibitor Drugs 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 108020004999 messenger RNA Proteins 0.000 description 7
• 238000003199 nucleic acid amplification method Methods 0.000 description 7
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 7
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 108060006633 protein kinase Proteins 0.000 description 7
• 238000011002 quantification Methods 0.000 description 7
• 230000009870 specific binding Effects 0.000 description 7
• 230000004083 survival effect Effects 0.000 description 7
• 230000008685 targeting Effects 0.000 description 7
• 108700024394 Exon Proteins 0.000 description 6
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
• 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 6
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
• ZFKJDNACAGAYFJ-UHFFFAOYSA-N [19-methyl-3-(2-methylpropyl)-14-oxo-3,13,19,20-tetrazahexacyclo[14.7.0.02,10.04,9.011,15.017,21]tricosa-1(16),2(10),4(9),5,7,11(15),17,20-octaen-7-yl] N-[[4-(dimethylamino)phenyl]methyl]carbamate Chemical compound CN(C1=CC=C(CNC(OC=2C=C3C=4C5=C(C6=C(C=4N(C3=CC=2)CC(C)C)CCC2=NN(C=C26)C)C(NC5)=O)=O)C=C1)C ZFKJDNACAGAYFJ-UHFFFAOYSA-N 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• 230000006907 apoptotic process Effects 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 238000002820 assay format Methods 0.000 description 6
• 239000011324 bead Substances 0.000 description 6
• 239000004202 carbamide Substances 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 239000000499 gel Substances 0.000 description 6
• 210000004408 hybridoma Anatomy 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 239000006166 lysate Substances 0.000 description 6
• 238000004949 mass spectrometry Methods 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• 238000001890 transfection Methods 0.000 description 6
• 210000004881 tumor cell Anatomy 0.000 description 6
• 241001430294 unidentified retrovirus Species 0.000 description 6
• CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 5
• HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 5
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 5
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
• 101150026109 INSR gene Proteins 0.000 description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
• 239000007993 MOPS buffer Substances 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
• 108091034117 Oligonucleotide Proteins 0.000 description 5
• 108010038807 Oligopeptides Proteins 0.000 description 5
• 102000015636 Oligopeptides Human genes 0.000 description 5
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 5
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 5
• 108090000631 Trypsin Proteins 0.000 description 5
• 102000004142 Trypsin Human genes 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 239000011230 binding agent Substances 0.000 description 5
• 230000010261 cell growth Effects 0.000 description 5
• 239000013592 cell lysate Substances 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 230000002759 chromosomal effect Effects 0.000 description 5
• 238000010276 construction Methods 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000029087 digestion Effects 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 238000013467 fragmentation Methods 0.000 description 5
• 238000006062 fragmentation reaction Methods 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 238000002372 labelling Methods 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 208000014018 liver neoplasm Diseases 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 239000008194 pharmaceutical composition Substances 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 230000011664 signaling Effects 0.000 description 5
• 238000006467 substitution reaction Methods 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 239000012588 trypsin Substances 0.000 description 5
• 238000011144 upstream manufacturing Methods 0.000 description 5
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 208000009956 adenocarcinoma Diseases 0.000 description 4
• GYABBVHSRIHYJR-UHFFFAOYSA-N alectinib hydrochloride Chemical compound Cl.CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 GYABBVHSRIHYJR-UHFFFAOYSA-N 0.000 description 4
• 239000012491 analyte Substances 0.000 description 4
• 239000000074 antisense oligonucleotide Substances 0.000 description 4
• 238000012230 antisense oligonucleotides Methods 0.000 description 4
• 239000007900 aqueous suspension Substances 0.000 description 4
• 210000001185 bone marrow Anatomy 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 239000013068 control sample Substances 0.000 description 4
• 230000009260 cross reactivity Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000010586 diagram Methods 0.000 description 4
• 239000012636 effector Substances 0.000 description 4
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 239000007850 fluorescent dye Substances 0.000 description 4
• 208000005017 glioblastoma Diseases 0.000 description 4
• 210000003917 human chromosome Anatomy 0.000 description 4
• 238000003119 immunoblot Methods 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 238000007918 intramuscular administration Methods 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 238000000021 kinase assay Methods 0.000 description 4
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
• 239000007791 liquid phase Substances 0.000 description 4
• 201000007270 liver cancer Diseases 0.000 description 4
• 230000014759 maintenance of location Effects 0.000 description 4
• 238000013507 mapping Methods 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 238000000386 microscopy Methods 0.000 description 4
• 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 4
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 230000017854 proteolysis Effects 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 238000012163 sequencing technique Methods 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 239000008096 xylene Substances 0.000 description 4
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 3
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
• 108060003951 Immunoglobulin Proteins 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 102000016979 Other receptors Human genes 0.000 description 3
• 108010033276 Peptide Fragments Proteins 0.000 description 3
• 102000007079 Peptide Fragments Human genes 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 238000011530 RNeasy Mini Kit Methods 0.000 description 3
• 239000012980 RPMI-1640 medium Substances 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 238000012300 Sequence Analysis Methods 0.000 description 3
• 206010041067 Small cell lung cancer Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 238000010804 cDNA synthesis Methods 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 125000002091 cationic group Chemical group 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 208000037516 chromosome inversion disease Diseases 0.000 description 3
• 238000001360 collision-induced dissociation Methods 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 230000030944 contact inhibition Effects 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 231100000676 disease causative agent Toxicity 0.000 description 3
• 239000003651 drinking water Substances 0.000 description 3
• 235000020188 drinking water Nutrition 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 102000018358 immunoglobulin Human genes 0.000 description 3
• 230000001965 increasing effect Effects 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 208000003849 large cell carcinoma Diseases 0.000 description 3
• 210000005265 lung cell Anatomy 0.000 description 3
• 210000002540 macrophage Anatomy 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• YPJUNDFVDDCYIH-UHFFFAOYSA-N perfluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 description 3
• 239000000825 pharmaceutical preparation Substances 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 239000002096 quantum dot Substances 0.000 description 3
• 238000003127 radioimmunoassay Methods 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000001177 retroviral effect Effects 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 241001515965 unidentified phage Species 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• NOBKLTMGMUWAFK-UHFFFAOYSA-N 4-chloro-6-pyrimidin-2-ylbenzene-1,3-diamine Chemical compound C1=C(Cl)C(N)=CC(N)=C1C1=NC=CC=N1 NOBKLTMGMUWAFK-UHFFFAOYSA-N 0.000 description 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 108090000565 Capsid Proteins Proteins 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 102000003952 Caspase 3 Human genes 0.000 description 2
• 108090000397 Caspase 3 Proteins 0.000 description 2
• 241001432959 Chernes Species 0.000 description 2
• 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 2
• 239000003298 DNA probe Substances 0.000 description 2
• AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
• 206010063045 Effusion Diseases 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 description 2
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
• 101000604039 Homo sapiens Sodium-dependent phosphate transport protein 2B Proteins 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 102100034343 Integrase Human genes 0.000 description 2
• 102000000646 Interleukin-3 Human genes 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• 102000057297 Pepsin A Human genes 0.000 description 2
• 108090000284 Pepsin A Proteins 0.000 description 2
• 108010004729 Phycoerythrin Proteins 0.000 description 2
• 241000276498 Pollachius virens Species 0.000 description 2
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
• 241001505332 Polyomavirus sp. Species 0.000 description 2
• 108091008611 Protein Kinase B Proteins 0.000 description 2
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 101150046784 Slc34a2 gene Proteins 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 108010006785 Taq Polymerase Proteins 0.000 description 2
• 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
• 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
• 108091008605 VEGF receptors Proteins 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 244000309464 bull Species 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 238000004422 calculation algorithm Methods 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 238000004891 communication Methods 0.000 description 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
• 230000009918 complex formation Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 238000004163 cytometry Methods 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 239000010432 diamond Substances 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 230000007783 downstream signaling Effects 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 238000007877 drug screening Methods 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 230000030279 gene silencing Effects 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 238000013537 high throughput screening Methods 0.000 description 2
• 102000049336 human SLC34A2 Human genes 0.000 description 2
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
• 230000008105 immune reaction Effects 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 238000011532 immunohistochemical staining Methods 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 239000003701 inert diluent Substances 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 238000004255 ion exchange chromatography Methods 0.000 description 2
• 238000005040 ion trap Methods 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 208000037841 lung tumor Diseases 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 239000012139 lysis buffer Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000001819 mass spectrum Methods 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 108091005601 modified peptides Proteins 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 238000007857 nested PCR Methods 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 231100000590 oncogenic Toxicity 0.000 description 2
• 230000002246 oncogenic effect Effects 0.000 description 2
• 108091008819 oncoproteins Proteins 0.000 description 2
• 102000027450 oncoproteins Human genes 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 239000013610 patient sample Substances 0.000 description 2
• 229940111202 pepsin Drugs 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000008196 pharmacological composition Substances 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 229910052697 platinum Inorganic materials 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 238000012340 reverse transcriptase PCR Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
• CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 229940048086 sodium pyrophosphate Drugs 0.000 description 2
• 210000004989 spleen cell Anatomy 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
• 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 239000012096 transfection reagent Substances 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 239000012130 whole-cell lysate Substances 0.000 description 2
• 238000001086 yeast two-hybrid system Methods 0.000 description 2
• 229910000166 zirconium phosphate Inorganic materials 0.000 description 2
• KUHSEZKIEJYEHN-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.OC[C@H](N)C(O)=O KUHSEZKIEJYEHN-BXRBKJIMSA-N 0.000 description 1
• PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
• 101150023956 ALK gene Proteins 0.000 description 1
• 229940126069 ALK kinase inhibitor Drugs 0.000 description 1
• RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 101100031730 Arabidopsis thaliana PUMP1 gene Proteins 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 1
• 108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 102000005367 Carboxypeptidases Human genes 0.000 description 1
• 108010006303 Carboxypeptidases Proteins 0.000 description 1
• 241000399988 Carinoma Species 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 102000005600 Cathepsins Human genes 0.000 description 1
• 108010084457 Cathepsins Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010061764 Chromosomal deletion Diseases 0.000 description 1
• 208000016718 Chromosome Inversion Diseases 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 101710094648 Coat protein Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 150000004921 Crizotinib derivatives Chemical class 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
• 206010015866 Extravasation Diseases 0.000 description 1
• 108091008794 FGF receptors Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 208000034951 Genetic Translocation Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
• 206010053759 Growth retardation Diseases 0.000 description 1
• 206010019695 Hepatic neoplasm Diseases 0.000 description 1
• 108090001101 Hepsin Proteins 0.000 description 1
• 102000004989 Hepsin Human genes 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101100130645 Homo sapiens MMP7 gene Proteins 0.000 description 1
• 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
• 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
• 101000610557 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp31 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
• 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 102000003746 Insulin Receptor Human genes 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
• 101710201824 Insulin receptor substrate 1 Proteins 0.000 description 1
• 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 1
• 101710201820 Insulin receptor substrate 2 Proteins 0.000 description 1
• 102100039064 Interleukin-3 Human genes 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 238000000719 MTS assay Methods 0.000 description 1
• 231100000070 MTS assay Toxicity 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• 102100030417 Matrilysin Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 229940049937 Pgp inhibitor Drugs 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
• 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710083689 Probable capsid protein Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 108010045292 Proto-Oncogene Proteins c-abl Proteins 0.000 description 1
• 102000005663 Proto-Oncogene Proteins c-abl Human genes 0.000 description 1
• 108020004518 RNA Probes Proteins 0.000 description 1
• 239000003391 RNA probe Substances 0.000 description 1
• 230000007022 RNA scission Effects 0.000 description 1
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
• 108091005682 Receptor kinases Proteins 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 101150035397 Ros1 gene Proteins 0.000 description 1
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
• KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 101001109965 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L7-A Proteins 0.000 description 1
• 101001109960 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L7-B Proteins 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108090001109 Thermolysin Proteins 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
• 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
• 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
• 102100040118 U4/U6 small nuclear ribonucleoprotein Prp31 Human genes 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 102000035181 adaptor proteins Human genes 0.000 description 1
• 108091005764 adaptor proteins Proteins 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000001371 alpha-amino acids Chemical class 0.000 description 1
• 235000008206 alpha-amino acids Nutrition 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 150000001408 amides Chemical group 0.000 description 1
• 230000002788 anti-peptide Effects 0.000 description 1
• 238000011091 antibody purification Methods 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 208000034615 apoptosis-related disease Diseases 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 108010062796 arginyllysine Proteins 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
• 210000004507 artificial chromosome Anatomy 0.000 description 1
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 238000005251 capillar electrophoresis Methods 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 239000008004 cell lysis buffer Substances 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 238000003200 chromosome mapping Methods 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 239000005515 coenzyme Substances 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 229940124301 concurrent medication Drugs 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000006552 constitutive activation Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000011443 conventional therapy Methods 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 238000010219 correlation analysis Methods 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 230000007711 cytoplasmic localization Effects 0.000 description 1
• 238000012303 cytoplasmic staining Methods 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 230000002498 deadly effect Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 235000019800 disodium phosphate Nutrition 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000012154 double-distilled water Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 229940121647 egfr inhibitor Drugs 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 210000003722 extracellular fluid Anatomy 0.000 description 1
• 230000036251 extravasation Effects 0.000 description 1
• XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000003197 gene knockdown Methods 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 229940080856 gleevec Drugs 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 239000002748 glycoprotein P inhibitor Substances 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 231100000001 growth retardation Toxicity 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 239000001307 helium Substances 0.000 description 1
• 229910052734 helium Inorganic materials 0.000 description 1
• SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 239000012456 homogeneous solution Substances 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 230000000887 hydrating effect Effects 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008073 immune recognition Effects 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 238000013198 immunometric assay Methods 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000002198 insoluble material Substances 0.000 description 1
• 229940076264 interleukin-3 Drugs 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 210000004880 lymph fluid Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000031864 metaphase Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 239000012120 mounting media Substances 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000003982 neuronal uptake Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 108091008104 nucleic acid aptamers Proteins 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 230000014207 opsonization Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 108700009251 p80(NPM-ALK) Proteins 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 230000008823 permeabilization Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 238000002733 pharmacodynamic assay Methods 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 210000004214 philadelphia chromosome Anatomy 0.000 description 1
• 108091005981 phosphorylated proteins Proteins 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 239000003531 protein hydrolysate Substances 0.000 description 1
• 230000026447 protein localization Effects 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 230000009822 protein phosphorylation Effects 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 108091006091 regulatory enzymes Proteins 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 208000011581 secondary neoplasm Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 239000004054 semiconductor nanocrystal Substances 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000006807 siRNA silencing Effects 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 230000007781 signaling event Effects 0.000 description 1
• 238000002553 single reaction monitoring Methods 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 235000011008 sodium phosphates Nutrition 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 238000011895 specific detection Methods 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
• 239000003656 tris buffered saline Substances 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229940038773 trisodium citrate Drugs 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 230000005909 tumor killing Effects 0.000 description 1
• 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
• 150000003668 tyrosines Chemical class 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1